1. Search Result
Search Result
Results for "

alterations

" in MedChemExpress (MCE) Product Catalog:

56

Inhibitors & Agonists

6

Screening Libraries

1

Biochemical Assay Reagents

6

Peptides

7

Natural
Products

3

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W250743

    Biochemical Assay Reagents Others
    Cresyl diphenyl phosphate is a compound that disrupts lipid homeostasis in zebrafish embryos, causing alterations in lipid content and lipidomic profiles, as well as affecting gene expression and energy homeostasis. |
    Cresyl diphenyl phosphate
  • HY-106856

    NT-11624

    iGluR Cancer
    Dimiracetam is an orally active compound, with anti-neuropathic activity. Dimiracetam inhibits hypersensitivity and neurological alterations, and inhibits Sorafenib (HY-10201)-induced neuropathy in cold stimulation rat models .
    Dimiracetam
  • HY-111130

    Histamine Receptor mAChR Neurological Disease Cancer
    Methapyrilene is a histamine antagonist, a pyridine chemical with anticholinergic activity. Methapyrilene can cause target organ-specific epigenetic alterations, such as a decrease in DNA methylation levels. Methapyrilene induces hepatocellular carcinoma in rats .
    Methapyrilene
  • HY-W067572

    (-)-Stobadine

    Reactive Oxygen Species (ROS) Cardiovascular Disease
    Stobadine is a potent antioxidant and prevents free radical induced alterations in ER membrane fluidity. Stobadine can be used for effective cardio- and neuroprotectants development based on antioxidant or free radical scavenging mechanisms of action .
    Stobadine
  • HY-W026842

    o-Benzoylbenzoic acid

    Drug Derivative Others
    2-Benzoylbenzoic acid is a Benzophenone (HY-Y0546) analog. 2-Benzoylbenzoic acid is non-phototoxic due to the alteration of the functional groups. 2-Benzoylbenzoic acid can be used to study the mechanism of phototoxicit .
    2-Benzoylbenzoic acid
  • HY-N6718
    Filipin III
    10+ Cited Publications

    Antibiotic Fungal Inflammation/Immunology
    Filipin III is the major component of Filipin, a 28-membered ring pentaene macrolide antifungal antibiotic produced by S. filipinensis, S. avermitilis and S. miharaensis. Filipin interacts with membrane sterols causing the alteration of membrane structure .
    Filipin III
  • HY-178174

    DNA/RNA Synthesis Topoisomerase Cancer
    MGB4 is a DNA minor groove binder. MGB4 binds to ARE-containing DNA and inhibition of topoisomerase I activity. MGB4 can impacts key cellular pathways, including inhibition oftranslation and alterations in sphingolipid and amino acid metabolism. MGB4 also reduces spermine and spermidine metabolism companied with Doxorubicin (HY-15142A). MGB4 can be used for the research of cancer, such as Prostate cancer .
    MGB4
  • HY-145528

    Endogenous Metabolite Metabolic Disease
    Heptanoyl-L-carnitine chloride (trans-3,4-methylene-heptanoylcarnitine) is an acylcarnitine. Heptanoyl-L-carnitine chloride causes exercise-induced alterations in the human metabolome in plasma and skeletal muscle tissue .
    Heptanoyl-L-carnitine chloride
  • HY-162320

    PPAR Metabolic Disease
    PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC50s of 3.98 and 15.42 μM against PPARγ and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .
    PPARγ agonist 12
  • HY-116046

    Melatonin Receptor Others
    GR 196429 is a melatonin receptor agonist with some selectivity for the MT1 subtype. GR 196429 produces both sleep-promoting effects and alterations of circadian rhythm, as well as stimulating melatonin release in mice .
    GR 196429
  • HY-N6036
    Ganoderic acid F
    1 Publications Verification

    Others Cancer
    Ganoderic acid F is a ganoderic acid. Ganoderic acid F exhibits antitumor and antimetastatic activities through inhibition of angiogenesis and alteration of proteins involving cell proliferation and/or cell death, carcinogenesis, oxidative stress, calcium signaling, and endoplasmic reticulum stress .
    Ganoderic acid F
  • HY-19586

    A 81-3138; HWA-138

    Phosphodiesterase (PDE) Endocrinology
    Albifylline (A 81-3138; HWA-138) is a Xanthine (HY-W017389) derivate. Albifylline reduces the shock-induced leukocyte adhesions to the sinusoidal endothelium in the liver after hemorrhagic shock and improves microvascular blood flow in the liver .
    Albifylline
  • HY-147250A
    Lirafugratinib hydrochloride
    1 Publications Verification

    RLY-4008 hydrochloride

    FGFR Cancer
    Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .
    Lirafugratinib hydrochloride
  • HY-147250
    Lirafugratinib
    1 Publications Verification

    RLY-4008

    FGFR Cancer
    Lirafugratinib (RLY-4008) is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .
    Lirafugratinib
  • HY-147268

    RAF/KIN_2787

    Raf p38 MAPK Cancer
    Exarafenib (RAF/KIN_2787) is an orally-available, selective pan-RAF inhibitor. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. Exarafenib has anticancer activity .
    Exarafenib
  • HY-153057

    Histone Methyltransferase Metabolic Disease Cancer
    PRMT5-IN-46 (compound 278) inhibits PRMT5 with IC50s of 1-10 μM. PRMT5 is a methyltransferase which is associated with specific genetic alterations. PRMT5-IN-46 can be used for research of proliferative diseases, metabolic disorders, and blood diseases .
    PRMT5-IN-46
  • HY-101494
    Temuterkib
    Maximum Cited Publications
    30 Publications Verification

    LY3214996

    ERK Cancer
    Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.
    Temuterkib
  • HY-136026

    BLU-5937

    P2X Receptor Inflammation/Immunology
    Camlipixant (BLU-5937) a potent, selective, non-competitive and orally active P2X3 homotrimeric receptor antagonist with an IC50 of 25 nM against hP2X3 homotrimeric. Camlipixant shows potent anti-tussive effect and no taste alteration. Camlipixant can be used for the research of unexplained, refractory chronic cough .
    Camlipixant
  • HY-P10371

    txCD47

    Reactive Oxygen Species (ROS) Thrombopoietin Receptor Inflammation/Immunology Cancer
    PKHB1 is a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS production, intracellular Ca 2+ accumulation, as well calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation through immunogenic cell death induction in breast cancer cells .
    PKHB1
  • HY-N6036R

    Reference Standards Others Cancer
    Ganoderic acid F (Standard) is the analytical standard of Ganoderic acid F. This product is intended for research and analytical applications. Ganoderic acid F is a ganoderic acid. Ganoderic acid F exhibits antitumor and antimetastatic activities through inhibition of angiogenesis and alteration of proteins involving cell proliferation and/or cell death, carcinogenesis, oxidative stress, calcium signaling, and endoplasmic reticulum stress .
    Ganoderic acid F (Standard)
  • HY-P10247

    Mitochondrial Metabolism Neurological Disease
    Amyloid precursor C-terminal peptide is cleaved from the C-terminus of Amyloid Precursor Protein (APP). Amyloid precursor C-terminal peptide accumulation causes mitochondrial morphology alteration and basal mitophagy failure, which indicates that amyloid precursor protein C-terminal peptide may correspond to an etiological trigger of Alzheimer’s disease (AD) pathology .
    Amyloid precursor C-terminal peptide
  • HY-B0337B

    Sulphadimethoxine 1000 µg/mL in methanol

    Antibiotic Infection
    Sulfadimethoxine 1000 μg/mL in methanol (Sulphadimethoxine 1000 μg/mL in methanol) is a sulfonamide antibiotic that inhibits the enzyme dihydropteroate synthase, thereby blocking dihydrofolic acid synthesis and disrupting folic acid production in prokaryotic organisms. Its antimicrobial activity extends to both Gram-positive and Gram-negative bacteria, as well as Chlamydia. Resistance to this compound may arise through alterations in dihydropteroate synthase or the activation of alternative pathways for folic acid synthesis.
    Sulfadimethoxine 1000 µg/mL in methanol
  • HY-P11205

    Cys-txCD47

    CD47 Reactive Oxygen Species (ROS) Thrombopoietin Receptor Inflammation/Immunology Cancer
    Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca + accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death .
    Cys-PKHB1
  • HY-W588717

    Biochemical Assay Reagents Others
    DBCO-Tetraacetyl mannosamine is an organic compound commonly used for chemical alteration and modification in biological research. It can be used to modify glycoproteins, cell surface molecules, and other biomolecules, and is widely used in biomarking and purification techniques. In addition, this compound is used as a carrier for drugs in certain drug controlled release systems. DBCO-Tetraacetyl mannosamine is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-Tetraacetyl mannosamine
  • HY-E70776

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET S891A is a mutant of RET. RET S891A Recombinant Human Active Protein Kinase is a recombinant RET S891A protein that can be used to study RET S891A-related functions .
    RET S891A Recombinant Human Active Protein Kinase
  • HY-P11205A

    Cys-txCD47 TFA

    CD47 Reactive Oxygen Species (ROS) Thrombopoietin Receptor Inflammation/Immunology Cancer
    Cys-PKHB1 (Cys-txCD47) TFA is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca + accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death .
    Cys-PKHB1 TFA
  • HY-121239

    NF-κB Neurological Disease Inflammation/Immunology Cancer
    Lemnalol is a potent agent for neuropathic pain. Lemnalol possesses potent anti-inflammatory, analgesic and anti-tumor activities. Lemnalol has the capacity to attenuate hyperalgesia and allodynia by modulation of neuroinflammatory processes in neuropathy. Lemnalol modulates LPS-induced alterations of left atrial (LA) calcium homeostasis and blocks the NF-κB pathways, which may contribute to the attenuation of lipopolysaccharide (LPS)-induced arrhythmogenesis and neuropathic pain. Lemnalolis a ylangene-type sesquiterpenoid compound, isolated from Lemnalia cervicorni .
    Lemnalol
  • HY-E70778

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804L is a mutant of RET. RET V804L Recombinant Human Active Protein Kinase is a recombinant RET V804L protein that can be used to study RET V804L-related functions .
    RET V804L Recombinant Human Active Protein Kinase
  • HY-123986
    CTPI-2
    10+ Cited Publications

    Mitochondrial Metabolism Inflammation/Immunology Cancer
    CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a KD of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity .
    CTPI-2
  • HY-E70780

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET Y791F is a mutant of RET. RET Y791F Recombinant Human Active Protein Kinase is a recombinant RET Y791F protein that can be used to study RET Y791F-related functions .
    RET Y791F Recombinant Human Active Protein Kinase
  • HY-E70767

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G691S is a mutant of RET. RET G691S Recombinant Human Active Protein Kinase is a recombinant RET G691S protein that can be used to study RET G691S-related functions .
    RET G691S Recombinant Human Active Protein Kinase
  • HY-E70774

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET R749T is a mutant of RET. RET R749T Recombinant Human Active Protein Kinase is a recombinant RET R749T protein that can be used to study RET R749T-related functions .
    RET R749T Recombinant Human Active Protein Kinase
  • HY-N0573
    Umbelliferone
    3 Publications Verification

    7-Hydroxycoumarin; Hydrangin; NSC 19790

    Apoptosis Fluorescent Dye Neurological Disease Inflammation/Immunology Cancer
    Umbelliferone (7-Hydroxycoumarin), a natural orally active product of the coumarin family, is a fluorescing compound which can be used as a sunscreen agent. Umbelliferone induces cell cycle arrest, apoptosis and DNA fragmentation in HepG2 cells. Umbelliferone exhibits significant anticancer effects. Umbelliferone attenuates the alteration characteristics of allergic airway inflammation. Umbelliferone displays the neuroprotective effects and cross the blood-brain barrier. Umbelliferone exhibits anti-inflammatory and antioxidant effects in chronic alcohol-fed rats .
    Umbelliferone
  • HY-E70777

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804E is a mutant of RET. RET V804E Recombinant Human Active Protein Kinase is a recombinant RET V804E protein that can be used to study RET V804E-related functions .
    RET V804E Recombinant Human Active Protein Kinase
  • HY-E70771

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET L730I is a mutant of RET. RET L730I Recombinant Human Active Protein Kinase is a recombinant RET L730I protein that can be used to study RET L730I-related functions .
    RET L730I Recombinant Human Active Protein Kinase
  • HY-E70779

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET V804M is a mutant of RET. RET V804M Recombinant Human Active Protein Kinase is a recombinant RET V804M protein that can be used to study RET V804M-related functions .
    RET V804M Recombinant Human Active Protein Kinase
  • HY-E70768

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810C is a mutant of RET. RET G810C Recombinant Human Active Protein Kinase is a recombinant RET G810C protein that can be used to study RET G810C-related functions .
    RET G810C Recombinant Human Active Protein Kinase
  • HY-E70773

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET M918T is a mutant of RET. RET M918T Recombinant Human Active Protein Kinase is a recombinant RET M918T protein that can be used to study RET M918T-related functions .
    RET M918T Recombinant Human Active Protein Kinase
  • HY-E70775

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET R813Q is a mutant of RET. RET R813Q Recombinant Human Active Protein Kinase is a recombinant RET R813Q protein that can be used to study RET R813Q-related functions .
    RET R813Q Recombinant Human Active Protein Kinase
  • HY-E70772

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET L730M is a mutant of RET. RET L730M Recombinant Human Active Protein Kinase is a recombinant RET L730M protein that can be used to study RET L730M-related functions .
    RET L730M Recombinant Human Active Protein Kinase
  • HY-E70769

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810R is a mutant of RET. RET G810R Recombinant Human Active Protein Kinase is a recombinant RET G810R protein that can be used to study RET G810R-related functions .
    RET G810R Recombinant Human Active Protein Kinase
  • HY-E70766

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET E762Q is a mutant of RET. RET E762Q Recombinant Human Active Protein Kinase is a recombinant RET E762Q protein that can be used to study RET E762Q-related functions .
    RET E762Q Recombinant Human Active Protein Kinase
  • HY-E70781

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET Y806H is a mutant of RET. RET Y806H Recombinant Human Active Protein Kinase is a recombinant RET Y806H protein that can be used to study RET Y806H-related functions .
    RET Y806H Recombinant Human Active Protein Kinase
  • HY-P11329

    Fluorescent Dye Others
    GFP11, 16 amino acids long, is a protein fusion tag. GFP11 presents proteins at the outer membrane of gram-negative bacteria and to label it with green fluorescence by complementation with externally added GFP1-10. GFP11 causes no significant perturbation of protein solubility and expression and alteration of the catalytic activity for enzyme CsBglA due to its small size. GFP11 can be used to form split-GFP system for biotechnological high-throughput and flow cytometry applications .
    GFP11
  • HY-E70770

    RET Cancer
    Rearranged during transfection (RET) is a transmembrane receptor protein tyrosine kinase (PTK) activated normally by forming ternary complexes with its cognate ligands and co-receptors. RET alterations by point mutations and gene fusions were found in diverse cancers. RET G810S is a mutant of RET. RET G810S Recombinant Human Active Protein Kinase is a recombinant RET G810S protein that can be used to study RET G810S-related functions .
    RET G810S Recombinant Human Active Protein Kinase
  • HY-174154

    FGFR Cancer
    INCB126503 is an orally activeM, selective FGFR2/3 Inhibitor with IC50 values of 70 nM (FGFR1), 2.1 nM (FGFR2), 1.2 nM (FGFR3), 0.92 nM (FGFR3-V555L), 0.85 nM (FGFR3-V555M) and 64 nM (FGFR4). INCB126503 suppresses FGFR signaling in vivo without causing hyperphosphatemia and shows antitumor efficacy in xenograft models harboring FGFR3 genetic alterations .
    INCB126503
  • HY-156002

    Paluratide

    Ras ERK Cancer
    LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .
    LUNA18
  • HY-172236

    BNC210; IW-2143

    nAChR Neurological Disease
    Soclenicant (BNC210) is an orally active α7 nAChR negative alteration modulator (NAM) with no apparent side effects. Soclenicant exhibits acute anxiolytic activity in rodent models of anxiety. Soclenicant inhibits rat and human α7 nAChR currents (in stably transfected cell lines) induced by acetylcholine, nicotine, choline, and the a7-specific agonist PNU-282987 (HY-12560A) with IC50 values in the range of 1.2 to 3 μM. Soclenicant can be used in studies of anxiety, trauma, and stressor-related disorders .
    Soclenicant
  • HY-N0573R

    7-Hydroxycoumarin (Standard); Hydrangin (Standard); NSC 19790 (Standard)

    Reference Standards Apoptosis Fluorescent Dye Neurological Disease Inflammation/Immunology Cancer
    Umbelliferone (Standard) (7-Hydroxycoumarin (Standard)) is the analytical standard of Umbelliferone (HY-N0573). This product is intended for research and analytical applications. Umbelliferone (7-Hydroxycoumarin), a natural orally active product of the coumarin family, is a fluorescing compound which can be used as a sunscreen agent. Umbelliferone induces cell cycle arrest, apoptosis and DNA fragmentation in HepG2 cells. Umbelliferone exhibits significant anticancer effects. Umbelliferone attenuates the alteration characteristics of allergic airway inflammation. Umbelliferone displays the neuroprotective effects and cross the blood-brain barrier. Umbelliferone exhibits anti-inflammatory and antioxidant effects in chronic alcohol-fed rats.
    Umbelliferone (Standard)
  • HY-N0573S

    7-Hydroxycoumarin-d5; Hydrangin-d5; NSC 19790-d5

    Isotope-Labeled Compounds Apoptosis Fluorescent Dye Neurological Disease Inflammation/Immunology Cancer
    Umbelliferone-d5 (7-Hydroxycoumarin-d5) is the deuterium labeled Umbelliferone (HY-N0573 ). Umbelliferone (7-Hydroxycoumarin), a natural orally active product of the coumarin family, is a fluorescing compound which can be used as a sunscreen agent. Umbelliferone induces cell cycle arrest, apoptosis and DNA fragmentation in HepG2 cells. Umbelliferone exhibits significant anticancer effects. Umbelliferone attenuates the alteration characteristics of allergic airway inflammation. Umbelliferone displays the neuroprotective effects and cross the blood-brain barrier. Umbelliferone exhibits anti-inflammatory and antioxidant effects in chronic alcohol-fed rats .
    Umbelliferone-d5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: